The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antigens, CD20
  • Antineoplastic Agents
  • Lymphoma, B-Cell
  • Neoplasm Recurrence, Local
  • Skin Neoplasms

abstract

  • Rituximab may be associated with the emergence of CD20-negative B-cell clones, potentially rendering a tumor insensitive to this drug. Conversely, following cessation of the drug, a re-expression of CD20 within the neoplastic cells may occur allowing therapeutic intervention with this monoclonal antibody. The loss of CD20 expression appears to be a direct effect of the drug on CD20 messenger RNA synthesis.

publication date

  • October 2005

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1111/j.0303-6987.2005.00305.x

PubMed ID

  • 16176299

Additional Document Info

start page

  • 616

end page

  • 21

volume

  • 32

number

  • 9